美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

iPath Bloomberg Lead Subindex Total Return ETN

44.95

+0.0000

成交量：- -

成交額：902.14

市值：121.59萬

市盈率：- -

高：44.95

開：44.95

低：44.95

收：44.95

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

創響生物與Ikena Oncology合併，融資7500萬美元，OX40 單克隆抗體能否撐起未來？

EWA賽道Luluchain以5000萬美元估值完成500萬美元機構輪融資，DG Capital領投

起底艾伯維神經科學領域

艾美达医药咨询

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/LD"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LD\",,,,,undefined,":{"symbol":"LD","market":"US","secType":"STK","nameCN":"iPath Bloomberg Lead Subindex Total Return ETN","latestPrice":44.95,"timestamp":1686168000000,"preClose":44.95,"halted":3,"volume":0,"delay":0,"floatShares":27049,"shares":27049,"eps":0,"marketStatus":"停牌","change":0,"latestTime":"04-02 09:05:55 EDT","open":44.95,"high":44.95,"low":44.95,"amount":902.14,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1743600600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":44.95,"sharesOutstanding":27049,"nav":44.6497,"aum":0,"bidAskSpread":0.058525,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LD\",,,,,undefined,":{"symbol":"LD","floatShares":27049,"roa":"--","roe":"--","lyrEps":0,"shares":27049,"dividePrice":0,"high":44.95,"amplitude":0,"preClose":44.95,"low":44.95,"week52Low":36.2,"pbRate":"--","week52High":51,"institutionHeld":0,"latestPrice":44.95,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":44.95,"prevYearClose":50.5648},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LD\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LD\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2494018455","title":"創響生物與Ikena Oncology合併，融資7500萬美元 ，OX40 單克隆抗體能否撐起未來？","url":"https://stock-news.laohu8.com/highlight/detail?id=2494018455","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494018455?lang=zh_tw&edition=fundamental","pubTime":"2024-12-25 14:01","pubTimestamp":1735106460,"startTime":"0","endTime":"0","summary":"合并后的公司将专注于开发针对OX40的单克隆抗体IMG-007，用于治疗特应性皮炎。IMG-007是一种具有Fc调节功能并沉默ADCC的OX40抗体，旨在最小化潜在的安全风险。结论单次剂量高达600 mg的IMG-007在健康参与者中耐受良好，并在高剂量下表现出延长的半衰期。IMG-007，作为一种非消耗性抗 OX40 单克隆抗体，通过抗体工程设计延长了半衰期，同时沉默了ADCC功能，与协和麒麟的Rocatinlimab设计正好相反。从疗效方面，也是OX40L抗体amlitelimab更优。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225145326a208a5e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225145326a208a5e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AE","BK4161","BK4218","CVR","LD","BK4539","PK","IKNA","BK4181","BK4138","BK4007"],"gpt_icon":0},{"id":"2484943739","title":"EWA賽道Luluchain以5000萬美元估值完成500萬美元機構輪融資，DG Capital領投","url":"https://stock-news.laohu8.com/highlight/detail?id=2484943739","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484943739?lang=zh_tw&edition=fundamental","pubTime":"2024-11-19 20:26","pubTimestamp":1732019160,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//flash/271205","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_zh_live","symbols":["LU1861559042.SGD","BK4551","IE00B19Z3B42.SGD","BK4503","BK4227","IE00BHPRN162.USD","BK4581","LU1989763690.USD","BK4528","BK4114","BK4585","BK4554","BK4504","DG","LD","BK4106","159940","BK4155","IE0002270589.USD","LU1430594728.SGD","IE00B19Z3581.USD","LU1989763427.SGD","IE00B7SZLL34.SGD","SQ","LU1585245621.USD","BK4588","LU1861558580.USD"],"gpt_icon":0},{"id":"2477881865","title":"起底艾伯維神經科學領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2477881865","media":"艾美达医药咨询","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477881865?lang=zh_tw&edition=fundamental","pubTime":"2024-10-21 15:00","pubTimestamp":1729494044,"startTime":"0","endTime":"0","summary":"2023年12月，艾伯维又斥资87亿美元收购神经科学制药Cerevel Therapeutics，拿下多款具有BIC潜力的管线，进一步巩固了艾伯维在神经科学领域的领先地位。艾伯维神经科学板块的部分产品及在研管线，图源：凯莱英药闻目前在神经科学领域，艾伯维的上市主要产品包括3款偏头痛药物Botox、Ubrelvy、Qulipta，精神分裂症药物Vraylar，以及帕金森病药物Duodopa。或许有一天，神经科学领域的产品也能超越自免产品，成为艾伯维的新王。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410211506199f531252&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410211506199f531252&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PD","LU0310800379.SGD","LU0965508806.USD","LU0114720955.EUR","LU0211328371.USD","BK4588","IE0009355771.USD","BK4559","ABBV","LU1169590202.USD","BK4581","LU0943347566.SGD","LU0029864427.USD","LU0256863902.USD","LU0882574055.USD","LU0861579265.USD","LU0820561818.USD","IE00B4R5TH58.HKD","BK4566","LU0965509010.AUD","LU0985320562.USD","IE00BVYPNV92.GBP","LU0553294199.USD","LU0949170772.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0203345920.USD","LU0456855351.SGD","BK4550","LU0234570918.USD","LU0310799852.SGD","LU0256863811.USD","IE00BSNM7G36.USD","IE00BDGV0183.EUR","LD","LU0170899867.USD","LU0689472784.USD","LU0211327993.USD","BK4139","LU1003077747.HKD","LU0795875086.SGD","BK4023","LU0198837287.USD","IE00BFTCPJ56.SGD","LU0708994859.HKD","IE00BVYPNW00.USD","LU0820561909.HKD","IE00B2B36J28.USD","BK4585","LU0795875169.SGD"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-06-14","symbol":"LD","reason":null,"defaultRemindTime":1686749400000,"announcedDate":"2023-04-25","type":"delisting","dateTimestamp":1686715200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.15,"buy":0.5,"hold":0.3,"sell":0.05,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":20,"updateTime":1684987200000}}}